Xtandi

Ask For a Blood test to identify AR-V7 in Circulating Tumor Cells if you are starting Xtandi or Zytiga

One of the hot topics in the prostate cancer community is the value of detecting AR-V7 tumor cells circulating in the blood. AR-V7 tumor cells in the blood predicts response or failure of treatment with enzalutamide (Xtandi) or abiraterone (Zytiga). A recent study found that men who have AR-V7 circulating tumor cells in their blood will not [...]

By Malecare|2017-10-19T10:45:55-04:00December 29th, 2016|abiraterone acetate, Advanced Prostate Cancer, Biomarkers and Prognostic Tools, Chemotherapy, CTCs, Drugs & Treatments, enzalutamide, taxanes, Uncategorized, Xtandi, Zytiga|1 Comment

Xtandi In Combination with Zytiga Is Not Better Than Either Drug Alone

A late-stage clinical trial designed to see if Xtandi in addition to Zytiga along with a steroid worked any better than either of these drugs separately (combining them v sequencing them) in men with advanced prostate cancer whose disease had worsened it was concluded that the combination was not superior to the individual drugs. This [...]